Monday, November 20, 2017 10:24:58 AM
"While we had originally intended to change the name of NOHO to IMBUTEK to pursue new acquisitions, we have now determined that the NOHO brand is too valuable and must stand alone, in light of recent product distribution and the new FDA registered and clinically tested medicine that is going into production. Sibbanac will change its name to IMBUTEK HOLDINGS CORP, which will allow us to expedite our original plan. Sibbanac is fully reporting and we are catching it up on its filings, which we'll have completed very quickly."
See my DRNK posts for more info.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM